Profile data is unavailable for this security.
About the company
Cartesian Therapeutics, Inc. is a clinical-stage company. The Company is engaged in developing messenger ribonucleic acids (mRNA) cell therapies for the treatment of autoimmune diseases. It is leveraging its proprietary technology and manufacturing platform, RNA Armory, to develop mRNA cell therapies for autoimmune diseases. Its lead asset e, Descartes-08, is an autologous mRNA chimeric antigen receptor T-cell therapy (CAR-T) directed against the B cell maturation antigen (BCMA), that the Company is developing for the treatment of autoimmune diseases. Descartes-08 is in Phase II clinical development. Descartes-15 is a next-generation, autologous anti-BCMA mRNA CAR-T. Using its proprietary technology and manufacturing platform, it designed Descartes-15 to be more resistant than Descartes-08 to recycling of the CAR upon multiple antigen exposures. It is developing Descartes-33 to deliver a combination of therapeutic proteins that target key drivers in the pathogenesis of autoimmunity.
- Revenue in USD (TTM)47.94m
- Net income in USD-244.83m
- Incorporated2007
- Employees38.00
- LocationCartesian Therapeutics Inc7495 New Horizon WayFREDERICK 21703United StatesUSA
- Phone+1 (301) 348-8698
- Fax+1 (617) 924-3454
- Websitehttps://www.cartesiantherapeutics.com/
More ▼
Mergers & acquisitions
| Acquired company | RNAC:NMQ since announced | Transaction value |
|---|---|---|
| Cartesian Therapeutics Inc | -41.07% | 6.81m |
Data delayed at least 15 minutes, as of Nov 12 2024 21:00 GMT.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| C4 Therapeutics Inc | 33.67m | -105.50m | 415.06m | 145.00 | -- | 1.71 | -- | 12.33 | -1.70 | -1.70 | 0.5217 | 3.44 | 0.095 | -- | 6.21 | 232,193.10 | -29.76 | -25.91 | -33.20 | -29.45 | -- | -- | -313.35 | -292.35 | -- | -- | 0.00 | -- | -33.25 | 1.40 | -3.37 | -- | -8.68 | -- |
| Akebia Therapeutics Inc | 169.88m | -45.99m | 418.47m | 167.00 | -- | -- | -- | 2.46 | -0.2207 | -0.2207 | 0.8338 | -0.2383 | 0.7684 | 1.33 | 6.20 | 1,017,240.00 | -20.80 | -37.42 | -31.00 | -56.00 | 84.79 | 69.13 | -27.07 | -82.25 | 1.21 | -2.52 | -- | -- | -33.46 | -1.30 | 44.89 | -- | -- | -- |
| ProQR Therapeutics NV | 19.93m | -22.95m | 419.38m | 157.00 | -- | 9.53 | -- | 21.04 | -0.2822 | -0.2822 | 0.2449 | 0.4155 | 0.1406 | -- | -- | 126,939.30 | -15.98 | -35.51 | -20.63 | -40.51 | -- | -- | -113.62 | -926.31 | -- | -- | 0.3687 | -- | 118.51 | 10.58 | 56.35 | -- | 34.45 | -- |
| 4D Molecular Therapeutics Inc | 20.22m | -109.89m | 419.39m | 201.00 | -- | 0.7121 | -- | 20.74 | -2.22 | -2.22 | 0.435 | 11.33 | 0.0416 | -- | -- | 137,544.20 | -22.60 | -32.67 | -23.39 | -34.90 | -- | -- | -543.51 | -617.15 | -- | -- | 0.00 | -- | 562.29 | 7.96 | 6.19 | -- | 46.26 | -- |
| Lexicon Pharmaceuticals Inc | 3.64m | -202.11m | 459.10m | 285.00 | -- | 1.91 | -- | 126.09 | -0.7783 | -0.7783 | 0.0139 | 0.6639 | 0.0106 | 0.7239 | 2.20 | 12,775.44 | -58.57 | -24.41 | -63.55 | -29.01 | 92.47 | 98.49 | -5,550.87 | -84.92 | 11.49 | -11.96 | 0.2931 | -- | 766.19 | -54.71 | -73.74 | -- | 37.68 | -- |
| Ginkgo Bioworks Holdings Inc | 184.34m | -897.68m | 460.56m | 1.22k | -- | 5.42 | -- | 2.50 | -18.03 | -18.03 | 3.69 | 1.62 | 0.0941 | -- | 4.20 | 151,342.40 | -45.83 | -- | -50.04 | -- | 80.22 | -- | -486.98 | -- | -- | -- | 0.00 | -- | -47.36 | -- | 57.58 | -- | -- | -- |
| Organogenesis Holdings Inc | 448.39m | -16.54m | 464.01m | 862.00 | -- | 1.76 | -- | 1.03 | -0.125 | -0.125 | 3.38 | 1.99 | 1.00 | 4.27 | 4.49 | 520,176.30 | -3.70 | 5.46 | -4.51 | 6.90 | 75.14 | 74.94 | -3.69 | 4.81 | 2.42 | 8.33 | 0.2001 | 0.00 | -3.94 | 17.49 | -68.16 | -- | 67.34 | -- |
| GH Research PLC | -100.00bn | -100.00bn | 470.33m | 49.00 | -- | 2.37 | -- | -- | -- | -- | -- | 3.82 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.0038 | -- | -- | -- | -58.47 | -- | -- | -- |
| Cartesian Therapeutics Inc | 47.94m | -244.83m | 472.61m | 38.00 | -- | 628.56 | -- | 9.86 | -37.79 | -37.79 | 3.25 | 0.0315 | 0.1708 | -- | 9.86 | 1,261,526.00 | -87.23 | -43.66 | -94.16 | -66.84 | -- | -- | -510.72 | -136.35 | -- | -0.3505 | 0.00 | -- | -76.53 | 95.83 | -721.02 | -- | -25.27 | -- |
| Grail Inc | 109.74m | -2.88bn | 475.05m | 1.37k | -- | 0.1763 | -- | 4.33 | -99.94 | -99.94 | 3.91 | 86.80 | -- | -- | -- | 81,894.77 | -- | -47.45 | -- | -48.55 | 44.06 | -- | -2,627.35 | -5,118.86 | -- | -- | 0.00 | -- | 67.61 | -- | 72.85 | -- | -4.22 | -- |
| Absci Corp | 3.25m | -92.26m | 486.02m | 155.00 | -- | 2.19 | -- | 149.55 | -0.9331 | -0.9331 | 0.0327 | 1.95 | 0.0128 | -- | 2.03 | 20,967.74 | -36.20 | -- | -40.23 | -- | -- | -- | -2,838.89 | -- | -- | -129.46 | 0.0284 | -- | -0.5046 | -- | -5.40 | -- | -- | -- |
| Contineum Therapeutics Inc | 0.00 | -31.45m | 498.54m | 31.00 | -- | 2.29 | -- | -- | -1.24 | -1.24 | 0.00 | 8.46 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 193.68 | -- | -- | -- |
| Foghorn Therapeutics Inc. | 25.52m | -91.22m | 515.90m | 116.00 | -- | -- | -- | 20.22 | -1.91 | -1.91 | 0.5133 | -0.5088 | 0.0821 | -- | -- | 219,956.90 | -29.34 | -31.35 | -35.57 | -35.69 | -- | -- | -357.53 | -777.33 | -- | -- | -- | -- | 77.63 | -- | 9.60 | -- | -4.50 | -- |
| Altimmune Inc | 409.00k | -101.35m | 522.37m | 59.00 | -- | 3.42 | -- | 1,277.19 | -1.62 | -1.62 | 0.0064 | 2.15 | 0.0023 | -- | 1.46 | 6,932.20 | -56.83 | -39.62 | -61.41 | -42.58 | -- | -- | -24,778.97 | -1,811.89 | -- | -- | 0.00 | -- | 726.47 | -47.15 | -4.41 | -- | -45.92 | -- |
| Prime Medicine Inc | 591.00k | -217.44m | 526.94m | 234.00 | -- | 2.68 | -- | 891.60 | -2.16 | -2.16 | 0.0058 | 1.64 | 0.0022 | -- | -- | 2,525.64 | -80.45 | -- | -88.55 | -- | -- | -- | -36,791.71 | -- | -- | -- | 0.00 | -- | -- | -- | -39.52 | -- | -- | -- |
Data as of Nov 12 2024. Currency figures normalised to Cartesian Therapeutics Inc's reporting currency: US Dollar USD
11.00%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Invus Public Equities Advisors LLCas of 12 Jul 2024 | 550.97k | 2.31% |
| Fidelity Management & Research Co. LLCas of 30 Jun 2024 | 509.34k | 2.13% |
| BlackRock Fund Advisorsas of 30 Jun 2024 | 372.13k | 1.56% |
| JPMorgan Investment Management, Inc.as of 30 Sep 2024 | 283.80k | 1.19% |
| Ikarian Capital LLCas of 30 Jun 2024 | 242.37k | 1.01% |
| The Vanguard Group, Inc.as of 30 Jun 2024 | 223.33k | 0.94% |
| SSgA Funds Management, Inc.as of 30 Jun 2024 | 153.67k | 0.64% |
| Geode Capital Management LLCas of 30 Jun 2024 | 132.96k | 0.56% |
| Logos Global Management LPas of 30 Jun 2024 | 90.00k | 0.38% |
| Boothbay Fund Management LLCas of 30 Jun 2024 | 68.54k | 0.29% |
More ▼
Data from 30 Jun 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
